- Home
- CWEN vs SLNO Comparison
CWEN vs SLNO Comparison
Compare CWEN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- SLNO
- Stock Information
- Founded
- CWEN 2012
- SLNO 1999
- Country
- CWEN United States
- SLNO United States
- Employees
- CWEN N/A
- SLNO N/A
- Industry
- CWEN Electric Utilities: Central
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CWEN Utilities
- SLNO Health Care
- Exchange
- CWEN Nasdaq
- SLNO Nasdaq
- Market Cap
- CWEN 3.4B
- SLNO 3.2B
- IPO Year
- CWEN 2013
- SLNO 2014
- Fundamental
- Price
- CWEN $28.87
- SLNO $76.78
- Analyst Decision
- CWEN Strong Buy
- SLNO Strong Buy
- Analyst Count
- CWEN 6
- SLNO 9
- Target Price
- CWEN $34.33
- SLNO $103.33
- AVG Volume (30 Days)
- CWEN 874.5K
- SLNO 955.8K
- Earning Date
- CWEN 04-30-2025
- SLNO 05-07-2025
- Dividend Yield
- CWEN 5.93%
- SLNO N/A
- EPS Growth
- CWEN 20.79
- SLNO N/A
- EPS
- CWEN 0.79
- SLNO N/A
- Revenue
- CWEN $1,406,000,000.00
- SLNO N/A
- Revenue This Year
- CWEN $10.50
- SLNO N/A
- Revenue Next Year
- CWEN $8.32
- SLNO N/A
- P/E Ratio
- CWEN $36.31
- SLNO N/A
- Revenue Growth
- CWEN 9.08
- SLNO N/A
- 52 Week Low
- CWEN $24.02
- SLNO $36.93
- 52 Week High
- CWEN $31.09
- SLNO $80.91
- Technical
- Relative Strength Index (RSI)
- CWEN 50.91
- SLNO 65.28
- Support Level
- CWEN $28.12
- SLNO $72.23
- Resistance Level
- CWEN $29.06
- SLNO $80.99
- Average True Range (ATR)
- CWEN 0.72
- SLNO 3.06
- MACD
- CWEN -0.01
- SLNO -0.37
- Stochastic Oscillator
- CWEN 48.80
- SLNO 64.59
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.